Share Price and Basic Stock Data
Last Updated: November 22, 2025, 9:03 am
| PEG Ratio | -18.53 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
MK Proteins Ltd operates within the Edible Oils & Solvent Extraction industry, with a current market capitalization of ₹244 Cr. The company reported a share price of ₹6.48, and its revenue from operations showed a notable upward trajectory, standing at ₹315 Cr for the fiscal year ending March 2023. This marked an increase from ₹256 Cr in the previous year. The trailing twelve months (TTM) revenue reached ₹325 Cr, indicating continued growth momentum. Quarterly sales figures reflect variability, with a significant rise to ₹86.87 Cr in March 2024 after a decline in previous quarters. The sales for the latest quarter of June 2023 reported at ₹76.20 Cr, showcasing a solid recovery. However, the upcoming quarters, particularly in March 2025, are projected to deliver even higher sales, with early indications suggesting ₹137.20 Cr. This aligns with the company’s strategy to enhance its market share in the edible oils segment, which remains competitive in India.
Profitability and Efficiency Metrics
MK Proteins Ltd’s profitability metrics demonstrate a mixed performance. The operating profit margin (OPM) for the fiscal year ending March 2025 stood at 4.82%, reflecting a decline from 6.16% in the previous year. The net profit for the same period was recorded at ₹8 Cr, translating to an earnings per share (EPS) of ₹0.22. The company’s return on equity (ROE) was reported at 12.08%, which is relatively low compared to industry benchmarks, indicating potential inefficiencies in utilizing shareholder funds. The interest coverage ratio (ICR) was robust at 11.68x, suggesting that the company can comfortably cover its interest obligations. Additionally, the cash conversion cycle (CCC) of 142 days indicates challenges in managing working capital effectively, particularly with inventory days increasing to 170. This could potentially strain liquidity if not addressed. Overall, while profitability remains a concern, the company’s ability to manage debt is commendable.
Balance Sheet Strength and Financial Ratios
The balance sheet of MK Proteins Ltd reveals a total borrowing of ₹39 Cr against reserves of ₹32 Cr as of March 2025. The total liabilities stood at ₹131 Cr, indicating an increase from ₹96 Cr in the previous year, reflecting a rising debt burden. The total debt to equity ratio is reported at 0.54, suggesting a moderate level of leverage. The current ratio of 2.01 indicates a healthy liquidity position, allowing the company to cover its short-term obligations. However, the quick ratio of 0.12 raises concerns about immediate liquidity, as it suggests reliance on inventory to meet current liabilities. The price-to-book value (P/BV) ratio of 3.26x indicates that the stock is trading at a premium, which may not be justified by its current profitability metrics. Furthermore, the return on capital employed (ROCE) of 17.54% reflects an efficient use of capital, although this figure is lower than historical highs, suggesting room for improvement in operational efficiency.
Shareholding Pattern and Investor Confidence
As of March 2025, the shareholding pattern of MK Proteins Ltd shows a strong promoter holding of 74.82%, indicating significant insider confidence in the company’s future. The public shareholding stands at 25.17%, with a notable increase in the number of shareholders from 344 in June 2023 to 72,294 by March 2025. This surge in retail investor participation highlights growing interest and confidence in the company’s prospects. However, foreign institutional investors (FIIs) remain absent, holding 0.00% of shares, which may reflect caution regarding the company’s growth potential or sector challenges. The absence of institutional backing could be a risk factor, as it limits access to larger pools of capital and market validation. Despite these dynamics, the stability in promoter shareholding suggests that the management is committed to long-term growth, which could reassure retail investors.
Outlook, Risks, and Final Insight
The outlook for MK Proteins Ltd hinges on its ability to navigate the challenges in profitability and operational efficiency. The consistent increase in revenue is promising; however, the declining profit margins and rising inventory days pose significant risks. The company must focus on enhancing its operational efficiencies to improve margins and manage working capital effectively. Additionally, the high promoter holding could be a double-edged sword, providing stability but also raising concerns about lack of external oversight. Future growth could be bolstered by expanding product lines or entering new markets, yet the absence of institutional investment suggests a need for strategic initiatives to attract broader investor confidence. Ultimately, while the company has strengths in market positioning and debt management, it faces critical challenges that could impact its future performance and investor sentiment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of MK Proteins Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| IEL Ltd | 100 Cr. | 7.69 | 10.3/3.87 | 3.37 | 0.00 % | 2.51 % | 1.91 % | 1.00 | |
| Evexia Lifecare Ltd | 323 Cr. | 1.72 | 4.40/1.52 | 226 | 3.02 | 0.00 % | 0.30 % | 0.32 % | 1.00 |
| Diligent Industries Ltd | 68.9 Cr. | 2.89 | 5.12/1.45 | 26.8 | 2.79 | 0.00 % | 7.06 % | 6.09 % | 1.00 |
| CIAN Agro Industries & Infrastructure Ltd | 4,237 Cr. | 1,514 | 3,633/321 | 2,087 | 33.0 | 0.00 % | 8.54 % | 1.06 % | 10.0 |
| BCL Industries Ltd | 1,048 Cr. | 35.5 | 58.3/33.0 | 10.1 | 28.9 | 0.73 % | 13.2 % | 13.0 % | 1.00 |
| Industry Average | 10,018.40 Cr | 177.65 | 169.00 | 33.77 | 0.18% | 14.09% | 12.05% | 4.00 |
Quarterly Result
| Metric | Mar 2017 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 53.59 | 76.20 | 13.64 | 68.86 | 86.87 | 57.33 | 33.69 | 39.48 | 137.20 | 114.95 |
| Expenses | 51.69 | 72.21 | 13.00 | 65.30 | 78.44 | 53.59 | 31.46 | 37.69 | 132.55 | 109.44 |
| Operating Profit | 1.90 | 3.99 | 0.64 | 3.56 | 8.43 | 3.74 | 2.23 | 1.79 | 4.65 | 5.51 |
| OPM % | 3.55% | 5.24% | 4.69% | 5.17% | 9.70% | 6.52% | 6.62% | 4.53% | 3.39% | 4.79% |
| Other Income | 0.01 | 0.00 | 0.03 | 0.01 | 0.41 | 0.00 | 0.21 | 0.25 | 0.02 | 0.00 |
| Interest | 0.69 | 0.52 | 0.04 | 0.11 | 0.40 | 0.33 | 0.03 | 0.07 | 0.67 | 0.70 |
| Depreciation | 0.30 | 0.12 | 0.12 | 0.12 | 0.18 | 0.07 | 0.07 | 0.11 | 0.09 | 0.10 |
| Profit before tax | 0.92 | 3.35 | 0.51 | 3.34 | 8.26 | 3.34 | 2.34 | 1.86 | 3.91 | 4.71 |
| Tax % | 36.96% | 25.67% | 21.57% | 25.75% | 29.42% | 25.45% | 25.21% | 25.81% | 28.64% | 25.27% |
| Net Profit | 0.57 | 2.49 | 0.41 | 2.48 | 5.83 | 2.48 | 1.74 | 1.38 | 2.80 | 3.51 |
| EPS in Rs | 0.02 | 0.07 | 0.01 | 0.07 | 0.16 | 0.07 | 0.05 | 0.04 | 0.07 | 0.09 |
Last Updated: August 20, 2025, 7:35 am
Below is a detailed analysis of the quarterly data for MK Proteins Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 114.95 Cr.. The value appears to be declining and may need further review. It has decreased from 137.20 Cr. (Mar 2025) to 114.95 Cr., marking a decrease of 22.25 Cr..
- For Expenses, as of Jun 2025, the value is 109.44 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 132.55 Cr. (Mar 2025) to 109.44 Cr., marking a decrease of 23.11 Cr..
- For Operating Profit, as of Jun 2025, the value is 5.51 Cr.. The value appears strong and on an upward trend. It has increased from 4.65 Cr. (Mar 2025) to 5.51 Cr., marking an increase of 0.86 Cr..
- For OPM %, as of Jun 2025, the value is 4.79%. The value appears strong and on an upward trend. It has increased from 3.39% (Mar 2025) to 4.79%, marking an increase of 1.40%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.02 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.02 Cr..
- For Interest, as of Jun 2025, the value is 0.70 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.67 Cr. (Mar 2025) to 0.70 Cr., marking an increase of 0.03 Cr..
- For Depreciation, as of Jun 2025, the value is 0.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.09 Cr. (Mar 2025) to 0.10 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 4.71 Cr.. The value appears strong and on an upward trend. It has increased from 3.91 Cr. (Mar 2025) to 4.71 Cr., marking an increase of 0.80 Cr..
- For Tax %, as of Jun 2025, the value is 25.27%. The value appears to be improving (decreasing) as expected. It has decreased from 28.64% (Mar 2025) to 25.27%, marking a decrease of 3.37%.
- For Net Profit, as of Jun 2025, the value is 3.51 Cr.. The value appears strong and on an upward trend. It has increased from 2.80 Cr. (Mar 2025) to 3.51 Cr., marking an increase of 0.71 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.09. The value appears strong and on an upward trend. It has increased from 0.07 (Mar 2025) to 0.09, marking an increase of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:56 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 122 | 123 | 145 | 165 | 172 | 157 | 194 | 311 | 256 | 315 | 245 | 268 | 325 |
| Expenses | 119 | 119 | 141 | 160 | 166 | 152 | 189 | 295 | 240 | 298 | 229 | 255 | 311 |
| Operating Profit | 3 | 4 | 4 | 5 | 6 | 5 | 5 | 16 | 16 | 17 | 17 | 13 | 14 |
| OPM % | 2% | 3% | 3% | 3% | 3% | 3% | 2% | 5% | 6% | 5% | 7% | 5% | 4% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Profit before tax | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 14 | 14 | 15 | 15 | 11 | 13 |
| Tax % | 33% | 32% | 31% | 35% | 35% | 28% | 26% | 27% | 27% | 27% | 28% | 27% | |
| Net Profit | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 10 | 10 | 11 | 11 | 8 | 9 |
| EPS in Rs | 0.82 | 1.40 | 1.20 | 0.04 | 0.04 | 0.04 | 0.05 | 0.28 | 0.27 | 0.29 | 0.30 | 0.22 | 0.25 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 400.00% | 0.00% | 10.00% | 0.00% | -27.27% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% | 100.00% | -100.00% | 400.00% | -400.00% | 10.00% | -10.00% | -27.27% |
MK Proteins Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 7% |
| 3 Years: | 2% |
| TTM: | 44% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 35% |
| 3 Years: | -7% |
| TTM: | -16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 49% |
| 3 Years: | 39% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 23% |
| 3 Years: | 18% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 10:00 am
Balance Sheet
Last Updated: June 16, 2025, 11:46 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.68 | 0.68 | 0.68 | 3 | 4 | 4 | 4 | 4 | 4 | 13 | 38 | 38 |
| Reserves | 1 | 2 | 3 | 2 | 11 | 13 | 15 | 25 | 35 | 37 | 24 | 32 |
| Borrowings | 28 | 20 | 26 | 31 | 33 | 26 | 31 | 25 | 37 | 46 | 20 | 39 |
| Other Liabilities | 2 | 13 | 10 | 12 | 8 | 4 | 7 | 13 | 10 | 8 | 15 | 22 |
| Total Liabilities | 32 | 35 | 39 | 47 | 56 | 47 | 57 | 67 | 86 | 103 | 96 | 131 |
| Fixed Assets | 3 | 6 | 7 | 7 | 6 | 4 | 3 | 2 | 3 | 3 | 3 | 4 |
| CWIP | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 26 | 29 | 32 | 40 | 50 | 43 | 53 | 65 | 83 | 100 | 88 | 120 |
| Total Assets | 32 | 35 | 39 | 47 | 56 | 47 | 57 | 67 | 86 | 103 | 96 | 131 |
Below is a detailed analysis of the balance sheet data for MK Proteins Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 38.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 38.00 Cr..
- For Reserves, as of Mar 2025, the value is 32.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Mar 2024) to 32.00 Cr., marking an increase of 8.00 Cr..
- For Borrowings, as of Mar 2025, the value is 39.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 20.00 Cr. (Mar 2024) to 39.00 Cr., marking an increase of 19.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 22.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.00 Cr. (Mar 2024) to 22.00 Cr., marking an increase of 7.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 131.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 96.00 Cr. (Mar 2024) to 131.00 Cr., marking an increase of 35.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2024) to 4.00 Cr., marking an increase of 1.00 Cr..
- For CWIP, as of Mar 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2024) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 88.00 Cr. (Mar 2024) to 120.00 Cr., marking an increase of 32.00 Cr..
- For Total Assets, as of Mar 2025, the value is 131.00 Cr.. The value appears strong and on an upward trend. It has increased from 96.00 Cr. (Mar 2024) to 131.00 Cr., marking an increase of 35.00 Cr..
However, the Borrowings (39.00 Cr.) are higher than the Reserves (32.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -25.00 | -16.00 | -22.00 | -26.00 | -27.00 | -21.00 | -26.00 | -9.00 | -21.00 | -29.00 | -3.00 | -26.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 19 | 16 | 27 | 10 | 39 | 25 | 18 | 24 | 42 | 19 | 5 | 2 |
| Inventory Days | 62 | 70 | 57 | 83 | 69 | 75 | 79 | 48 | 80 | 91 | 134 | 170 |
| Days Payable | 6 | 39 | 22 | 23 | 12 | 6 | 8 | 10 | 8 | 6 | 19 | 29 |
| Cash Conversion Cycle | 75 | 47 | 62 | 70 | 97 | 94 | 89 | 62 | 114 | 104 | 120 | 142 |
| Working Capital Days | 69 | 11 | 9 | 20 | 44 | 32 | 36 | 36 | 55 | 57 | 77 | 81 |
| ROCE % | 10% | 14% | 13% | 12% | 11% | 8% | 8% | 29% | 23% | 20% | 19% | 13% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.22 | 0.30 | 8.51 | 24.42 | 24.91 |
| Diluted EPS (Rs.) | 0.22 | 0.30 | 8.51 | 24.42 | 24.91 |
| Cash EPS (Rs.) | 0.23 | 0.31 | 9.11 | 26.61 | 27.09 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.85 | 1.63 | 40.18 | 94.95 | 70.34 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.85 | 1.63 | 40.18 | 94.95 | 70.34 |
| Revenue From Operations / Share (Rs.) | 7.13 | 6.54 | 251.64 | 613.52 | 745.89 |
| PBDIT / Share (Rs.) | 0.34 | 0.45 | 13.66 | 37.85 | 38.31 |
| PBIT / Share (Rs.) | 0.33 | 0.44 | 13.06 | 35.66 | 36.13 |
| PBT / Share (Rs.) | 0.30 | 0.41 | 11.67 | 33.67 | 34.34 |
| Net Profit / Share (Rs.) | 0.22 | 0.29 | 8.51 | 24.42 | 24.91 |
| PBDIT Margin (%) | 4.82 | 6.94 | 5.42 | 6.16 | 5.13 |
| PBIT Margin (%) | 4.69 | 6.73 | 5.18 | 5.81 | 4.84 |
| PBT Margin (%) | 4.27 | 6.29 | 4.63 | 5.48 | 4.60 |
| Net Profit Margin (%) | 3.13 | 4.56 | 3.38 | 3.98 | 3.33 |
| Return on Networth / Equity (%) | 12.08 | 18.35 | 21.17 | 25.71 | 35.41 |
| Return on Capital Employeed (%) | 17.54 | 26.54 | 30.87 | 35.13 | 44.53 |
| Return On Assets (%) | 6.43 | 11.64 | 10.14 | 11.82 | 15.42 |
| Long Term Debt / Equity (X) | 0.01 | 0.00 | 0.05 | 0.06 | 0.15 |
| Total Debt / Equity (X) | 0.54 | 0.31 | 0.88 | 0.92 | 0.83 |
| Asset Turnover Ratio (%) | 2.36 | 2.44 | 3.30 | 3.33 | 5.02 |
| Current Ratio (X) | 2.01 | 2.53 | 1.96 | 1.88 | 1.92 |
| Quick Ratio (X) | 0.12 | 0.19 | 0.58 | 0.74 | 0.79 |
| Inventory Turnover Ratio (X) | 2.81 | 2.73 | 4.23 | 4.49 | 5.77 |
| Interest Coverage Ratio (X) | 11.68 | 16.02 | 9.86 | 18.96 | 21.31 |
| Interest Coverage Ratio (Post Tax) (X) | 8.60 | 11.53 | 7.14 | 13.23 | 14.86 |
| Enterprise Value (Cr.) | 264.44 | 389.87 | 957.87 | 116.65 | 57.72 |
| EV / Net Operating Revenue (X) | 0.98 | 1.59 | 3.04 | 0.45 | 0.18 |
| EV / EBITDA (X) | 20.49 | 22.85 | 56.03 | 7.39 | 3.61 |
| MarketCap / Net Operating Revenue (X) | 0.84 | 1.51 | 2.90 | 0.31 | 0.10 |
| Price / BV (X) | 3.26 | 6.07 | 18.17 | 2.02 | 1.13 |
| Price / Net Operating Revenue (X) | 0.84 | 1.51 | 2.90 | 0.31 | 0.10 |
| EarningsYield | 0.03 | 0.03 | 0.01 | 0.12 | 0.31 |
After reviewing the key financial ratios for MK Proteins Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has decreased from 0.30 (Mar 24) to 0.22, marking a decrease of 0.08.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has decreased from 0.30 (Mar 24) to 0.22, marking a decrease of 0.08.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 3. It has decreased from 0.31 (Mar 24) to 0.23, marking a decrease of 0.08.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.85. It has increased from 1.63 (Mar 24) to 1.85, marking an increase of 0.22.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.85. It has increased from 1.63 (Mar 24) to 1.85, marking an increase of 0.22.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.13. It has increased from 6.54 (Mar 24) to 7.13, marking an increase of 0.59.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.34, marking a decrease of 0.11.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.33. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.33, marking a decrease of 0.11.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.41 (Mar 24) to 0.30, marking a decrease of 0.11.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 2. It has decreased from 0.29 (Mar 24) to 0.22, marking a decrease of 0.07.
- For PBDIT Margin (%), as of Mar 25, the value is 4.82. This value is below the healthy minimum of 10. It has decreased from 6.94 (Mar 24) to 4.82, marking a decrease of 2.12.
- For PBIT Margin (%), as of Mar 25, the value is 4.69. This value is below the healthy minimum of 10. It has decreased from 6.73 (Mar 24) to 4.69, marking a decrease of 2.04.
- For PBT Margin (%), as of Mar 25, the value is 4.27. This value is below the healthy minimum of 10. It has decreased from 6.29 (Mar 24) to 4.27, marking a decrease of 2.02.
- For Net Profit Margin (%), as of Mar 25, the value is 3.13. This value is below the healthy minimum of 5. It has decreased from 4.56 (Mar 24) to 3.13, marking a decrease of 1.43.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.08. This value is below the healthy minimum of 15. It has decreased from 18.35 (Mar 24) to 12.08, marking a decrease of 6.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.54. This value is within the healthy range. It has decreased from 26.54 (Mar 24) to 17.54, marking a decrease of 9.00.
- For Return On Assets (%), as of Mar 25, the value is 6.43. This value is within the healthy range. It has decreased from 11.64 (Mar 24) to 6.43, marking a decrease of 5.21.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.54. This value is within the healthy range. It has increased from 0.31 (Mar 24) to 0.54, marking an increase of 0.23.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 2.36. It has decreased from 2.44 (Mar 24) to 2.36, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has decreased from 2.53 (Mar 24) to 2.01, marking a decrease of 0.52.
- For Quick Ratio (X), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 1. It has decreased from 0.19 (Mar 24) to 0.12, marking a decrease of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.81. This value is below the healthy minimum of 4. It has increased from 2.73 (Mar 24) to 2.81, marking an increase of 0.08.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.68. This value is within the healthy range. It has decreased from 16.02 (Mar 24) to 11.68, marking a decrease of 4.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.60. This value is within the healthy range. It has decreased from 11.53 (Mar 24) to 8.60, marking a decrease of 2.93.
- For Enterprise Value (Cr.), as of Mar 25, the value is 264.44. It has decreased from 389.87 (Mar 24) to 264.44, marking a decrease of 125.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has decreased from 1.59 (Mar 24) to 0.98, marking a decrease of 0.61.
- For EV / EBITDA (X), as of Mar 25, the value is 20.49. This value exceeds the healthy maximum of 15. It has decreased from 22.85 (Mar 24) to 20.49, marking a decrease of 2.36.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 1.51 (Mar 24) to 0.84, marking a decrease of 0.67.
- For Price / BV (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has decreased from 6.07 (Mar 24) to 3.26, marking a decrease of 2.81.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 1.51 (Mar 24) to 0.84, marking a decrease of 0.67.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in MK Proteins Ltd:
- Net Profit Margin: 3.13%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.54% (Industry Average ROCE: 14.09%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.08% (Industry Average ROE: 12.05%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 28.3 (Industry average Stock P/E: 169)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.54
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.13%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Edible Oils & Solvent Extraction | Naraingarh Road, Village Garnala, Ambala District Haryana 134003 | compliancemkproteins@gmail.com http://www.mkproteins.in |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Parvind Kumar | Chairman |
| Mr. Parmod Kumar | Managing Director |
| Mr. Vinod Kumar | Whole Time Director |
| Ms. Laxmi Mandal | Independent Director |
| Mr. Tej Mohan Singh | Independent Director |
| Mrs. Shipra Jain | Independent Director |
| Mr. Raj Kumar | Non Executive Director |
FAQ
What is the intrinsic value of MK Proteins Ltd?
MK Proteins Ltd's intrinsic value (as of 26 November 2025) is 5.61 which is 12.34% lower the current market price of 6.40, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 239 Cr. market cap, FY2025-2026 high/low of 9.78/5.37, reserves of ₹32 Cr, and liabilities of 131 Cr.
What is the Market Cap of MK Proteins Ltd?
The Market Cap of MK Proteins Ltd is 239 Cr..
What is the current Stock Price of MK Proteins Ltd as on 26 November 2025?
The current stock price of MK Proteins Ltd as on 26 November 2025 is 6.40.
What is the High / Low of MK Proteins Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of MK Proteins Ltd stocks is 9.78/5.37.
What is the Stock P/E of MK Proteins Ltd?
The Stock P/E of MK Proteins Ltd is 28.3.
What is the Book Value of MK Proteins Ltd?
The Book Value of MK Proteins Ltd is 1.96.
What is the Dividend Yield of MK Proteins Ltd?
The Dividend Yield of MK Proteins Ltd is 0.00 %.
What is the ROCE of MK Proteins Ltd?
The ROCE of MK Proteins Ltd is 12.9 %.
What is the ROE of MK Proteins Ltd?
The ROE of MK Proteins Ltd is 12.4 %.
What is the Face Value of MK Proteins Ltd?
The Face Value of MK Proteins Ltd is 1.00.